Canada halts AstraZeneca COVID-19 vaccine for people 55 and under, citing 'uncertainty' on blood clots

AstraZeneca COVID-19 vaccine
(Image credit: Dan Kitwood/Getty Images)

Canada's 13 provinces and territories, on advice from the National Advisory Committee on Immunization, suspended use of AstraZeneca's vaccine on people 55 and younger Monday. The advisory committee said its recommendation was a "precautionary measure" due to "rare" cases of blood clots in Europe, mostly affecting women under 55. "There is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccines to adults under 55 given the potential risks," said Dr. Shelley Deeks, the committee's vice chair.

AstraZeneca is a relatively small part of Canada's COVID-19 vaccine strategy, but it is hugely important for the global vaccination effort and is widely used in Britain. Europe's drug regulator said there is no evidence of an overall increase in blood clots and the vaccine is safe and effective to use. Canadian officials said they want more information about the blood clots, especially in young women. There have been no reports of blood clots in Canada, and the country is still using the vaccine for those over 55.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.